Researchers have revealed the final results of the first study that measured the impact of PrEP on reducing HIV in a large population.
Significantly more gay and bisexual men are using HIV pre-exposure prophylaxis (PrEP) due to increased confidence in the benefits of HIV treatment for prevention.
Eradicating a virus from the community requires everyone to have access to prevention, as is the case with tuberculosis. So why not HIV?
An increase in condomless sex in pre-exposure prophylaxis users is predictable as preventing HIV is the key motivator for condom use among gay and bisexual men.
A recommendation that the HIV prevention drug PrEP be approved for public subsidy has been hailed as an essential step in Australia's response to HIV.
The Kirby Institute has been a key player in NSW’s partnership response to HIV, which has reached a historic milestone.
UNSW researcher Martin Holt will explore the social impacts of rapid changes in HIV prevention when he delivers a free public lecture on 22 February.
The Kirby Institute at UNSW has welcomed the Therapeutic Goods Administration's approval of antiretroviral drug Truvada as pre-exposure prophylaxis (PrEP) in Australia.
A landmark clinical trial led by UNSW researchers aims to halve new HIV infections in NSW within two years and 'virtually eliminate' HIV transmission by 2020.
The Kirby Insitute at UNSW has launched a feasibility study to examine whether HIV negative people can take combination drug therapy to reduce their risk of acquiring the virus.